Here is the September edition of the Ohio State University Research News Service. The stories below report on only a few of the research projects under way here. If you have any questions about this work or other Ohio State research, please call.

Study Suggests Why Estrogen Not Helpful Against Heart Disease

Researchers long believed that post-menopausal women undergoing hormone replacement therapy may also gain an added reduction in their risk of developing coronary artery disease. But when a major study released last year showed no such reduction in risk, cardiologists wondered why. Now, a new study may reveal part of the reason: The gene that’s responsible for making receptors to the hormone estrogen might be “out of service” as a consequence of atherosclerosis, preventing the formation of the receptor. (From a recent issue of the journal Cardiovascular Research.) Contact: Pascal Goldschmidt, (614) 688-5779.

New Design Will Help Cool Microelectronics More Efficiently

As microelectronics pack more high-powered computer chips into ever-shrinking spaces, cooling these devices becomes more difficult. Ohio State researchers have developed a heat sink, or cooling system, that is more efficient than current designs. In simulations, a microelectronic circuit using the new heat sink design heated up only about one third as much as a circuit using a conventional heat sink. Makers of computers, lasers, and other devices may benefit from the new design. (From a recent issue of the International Journal of Heat and Mass Transfer.) Contact: Kambiz Vafai, (614) 292-6560.

Common Drug Associated with Improved Performance in Race Horses

A drug legally given before a race to horses for a certain medical condition is suspected of having a positive effect on their performance. The drug, called furosemide, is often given to racehorses with a history of bleeding in the respiratory tract -- or exercise-induced pulmonary hemorrhaging. The study found horses given furosemide prior to a race were 1.4 times more likely to win a race, 1.2 times more likely to finish in the top three and earned an average of $416.00 more than the horses not receiving the drug. (From a recent issue of the Journal of the American Veterinary Medical Association.) Contact: Kenneth Hinchcliff, (614) 292-7105.


Jeff Grabmeier, Managing Editor
Earle Holland, Director, Science Communications

Return to the Research page
Return to the OSU Homepage
Go to the Research, Newsfeature, and Cancer Report Archive